Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935958 · ClinicalTrials.gov registry record · NA
Curcumin in Kidney Transplant Recipients
A NA study of Disorder Related to Renal Transplantation, sponsored by University of Illinois at Chicago.
- Active
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03935958: Active NA study of Disorder Related to Renal Transplantation, sponsored by University of Illinois at Chicago.
NCT03935958 is a NA study of Disorder Related to Renal Transplantation that is active but no longer recruiting, run by University of Illinois at Chicago. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03935958, a NA study of Disorder Related to Renal Transplantation, is active but no longer recruiting, sponsored by University of Illinois at Chicago.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.
Primary Outcome
Change in GFR at 3, 6 and 12 months
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Curcumin
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2025-12 |
| Phase | NA |
What the registry record for NCT03935958 still lists
NCT03935958 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Disorder Related to Renal Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03935958 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03935958 about?
NCT03935958 is a clinical study titled "Curcumin in Kidney Transplant Recipients". The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be...
What is the current status of trial NCT03935958?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 14 participants. The study started on 2019-11-01. Estimated completion is 2025-12.
What conditions does trial NCT03935958 study?
This clinical trial studies the following conditions: Disorder Related to Renal Transplantation.
What interventions are being tested in trial NCT03935958?
The interventions under investigation include: Placebo (OTHER), Curcumin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03935958?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03935958 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Disorder Related to Renal Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03935958's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy